Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
FDA Approved | Lung Cancer

FDA Approves Gavreto for Metastatic Non-Small Cell Lung Cancer

Posted on September 7, 2020
Post Views: 578

FDA ApprovedThe Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for treatment of patients with metastatic non-small cell lung cancer (NSCLC). Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy. Gavreto is a once-daily, oral precision therapy that selectively inhibits RET-altered cancers. It has been approved for treatment of adult patients with metastatic rearranged during transfection as detected by an FDA approved test. It is designed to selectively and potently inhibit RET alterations that drive many cancer types.

Jeff Albers, Chief Executive Officer of Blueprint Medicines said, “GAVRETO is the second breakthrough therapy discovered by Blueprint Medicines that has received FDA approval in 2020, less than 10 years since the company started operations. This progress reflects the power of our scientific platform, our focus on delivering transformative outcomes to patients and our urgency to address important medical needs.”

Gavreto has received approval by FDA upon verification and description of clinical benefit in a confirmatory trial. In 87 patients previously treated with platinum-based chemotherapy, the overall response rate was 57% with a 5.7% complete response rate. In 27 treatment-naïve patients who were ineligible for platinum-based chemotherapy, the overall response rate was 70% with an 11% complete response rate and median duration of response was 9 months. The approval is based on data from Phase 1/2 arrow clinical trial, which showed efficacy for Gavreto in patients. This approval represents an important advance with the potential to change standards of care for lung cancer patients.

Blueprint Medicines and Genentech plans to make Gavreto available in the US within a week. It will be available in 100mg dose strength and the recommended dose is 400mg once daily.

The information shared in this blog is for educational purposes only. If you face any symptoms, you should contact your healthcare practitioner immediately.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d